相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial
Gregory G. Stone et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia
David L. Paterson et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2020)
Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17
Krystyna M. Kazmierczak et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime
Ryan K. Shields et al.
CLINICAL INFECTIOUS DISEASES (2020)
Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales
Antonio Vena et al.
ANTIBIOTICS-BASEL (2020)
Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers
Rodrigo E. Mendes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points
Aatoni Torres et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets
Rodrigo E. Mendes et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
Gregory G. Stone et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis
Neta Sternbach et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Carbapenem-Sparing Therapy for Extended-Spectrum β-Lactamase-Producing E coli and Klebsiella pneumoniae Bloodstream Infection The Search Continues
Mary K. Hayden et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL-and AmpC-producing Enterobacteriaceae
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Simon Portsmouth et al.
LANCET INFECTIOUS DISEASES (2018)
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
Xinyu Qin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets
Rodrigo E. Mendes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates
Rodrigo E. Mendes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M. Wagenlehner et al.
CLINICAL INFECTIOUS DISEASES (2016)
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
John E. Mazuski et al.
CLINICAL INFECTIOUS DISEASES (2016)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Yehuda Carmeli et al.
LANCET INFECTIOUS DISEASES (2016)
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial
Patrick N. A. Harris et al.
Trials (2015)
In Vitro Susceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations
Henry Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial
Christopher Lucasti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
Jose A. Vazquez et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections
John F. Mohr
CLINICAL INFECTIOUS DISEASES (2008)
Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia:: a systematic review and meta-analysis
Mitchell J. Schwaber et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study
H Wisplinghoff et al.
CLINICAL INFECTIOUS DISEASES (2004)
分享论文
